Related to PsychoGenics to Assess AstraZeneca Candidates for Treating Central Nervous System Disorders

• AstraZeneca Pays Dynavax $3M to Speed Up Start of Asthma Drug Trials
  
• First Phase III Study with Targacept and AstraZeneca’s Adjunctive Antidepressant Misses Primary Endpoint
  
• Neoprobe Licenses AstraZeneca’s Alzheimer Plaque Imaging Agent
  
• AstraZeneca, Targacept’s TC-5214 Fails as Adjunct to Antidepressants
  
• Hutchinson, AstraZeneca Ink Deal for c-Met Inhibitor with $20M Up Front
  
• AstraZeneca Takes FDA to Court Over Generic Antipsychotic Labeling
  
• Targacept, AstraZeneca Ditch Depression Drug After All Four Phase III Studies Fail
  
• AstraZeneca Forges Pact Around Five Amgen Clinical-Stage Anti-Inflammatory mAbs
  
• NMR Structural Biology Firm Signs First Drug Discovery Collaboration with AstraZeneca
  
• AstraZeneca, Rigel Sign Potentially $100M Asthma Drug Deal
  
• AstraZeneca Acquires Neurodegenerative Disease Assets and Establishes Research Consortium
  
• Hundreds of Mutations Potentially Linked to Autism
  
• AZ Licensing Vanderbilt Neuroscience Compounds
  
• Horizon, AstraZeneca Seek Kinase-Targeting Cancer Drugs
  
• AstraZeneca, BIND Enter $200M+ Cancer Nanomedicine Agreement
  
• AstraZeneca Taps Jubilant for Discovery Work
  
• Targacept to Receive $10M as AstraZeneca Scales Up CNS Disorder Partnership
  
• KineMed’s Neurogenesis Technology Added to PsychoGenics’ Platform for CNS Drug Discovery
  
• Evotec and PsychoGenics Ally to Offer Integrated CNS Drug Discovery Solutions
  
• Targacept and AZ Restructure Partnership as Success Proves Elusive